Azaindole Derivatives Dual Mechanism Nicotinic Agonist Dopamine Inhibitor
Solution Overview
Problem
Current compounds lack a dual mechanism of action that combines partial agonism on nicotinic acetylcholine receptors and dopamine reuptake inhibition, which is necessary for effectively treating disorders related to nicotinic receptor and dopamine transporter dysregulation.
Innovation Solution
Development of azaindole derivatives with specific structural features that exhibit partial agonistic activity on nicotinic acetylcholine receptors and inhibit dopamine reuptake, allowing for their use in treating various neurological and neuropsychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If compounds are designed to target only nicotinic receptors or only dopamine transporters, then mechanism of action is simple and selective, but therapeutic effectiveness for disorders involving both systems is insufficient
Solution Approach 1:
The patent merges two distinct pharmacological mechanisms into a single compound: partial agonism at nicotinic acetylcholine receptors and inhibition of dopamine reuptake. This is achieved through the azaindole derivative structure that simultaneously interacts with both target systems, providing dual therapeutic action for disorders involving both nicotinic and dopaminergic pathways.
Solution Approach 2:
The azaindole derivative compound serves multiple functions: it acts as a partial agonist at nicotinic receptors to modulate acetylcholine signaling, simultaneously functions as a dopamine reuptake inhibitor to increase synaptic dopamine levels, and provides therapeutic effects for multiple disorder types including addiction, schizophrenia, and neurodegenerative conditions through this multi-functional mechanism.
2Power
If full agonist activity is used on nicotinic receptors, then receptor activation is strong, but rapid desensitization occurs leading to loss of function
Solution Approach 1:
The patent employs partial agonist activity at nicotinic receptors rather than full agonism. This partial activation provides sufficient receptor stimulation to achieve therapeutic effects while avoiding the rapid desensitization and functional inhibition that occurs with full agonists. The balanced partial agonism maintains reliable receptor function over extended periods.
3Object-affected harmful factors
If nicotinic receptor antagonists are used to inhibit hyperactivity, then dopaminergic system hyperactivity is reduced, but therapeutic benefit is limited to conditions where receptor inhibition is sufficient
Solution Approach 1:
The azaindole derivative acts as an intermediary substance that modulates dopaminergic hyperactivity indirectly through dual mechanisms: partial nicotinic receptor agonism to regulate presynaptic release and dopamine reuptake inhibition to control synaptic clearance. This intermediary approach provides versatile therapeutic benefits across multiple disorder types beyond what simple antagonism achieves.
Data Source
AI summary
The invention concerns azaindole derivatives having the general formula (I) wherein the symbols have the meanings given in the specification. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors.